NCT05866692View on ClinicalTrials.gov

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Solid Tumor, Adult
Interventions
DRUG

TY-2699a

"TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results"

Trial Locations (2)

100021

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing

250117

RECRUITING

Shandong Cancer Hospital, Jinan

All Listed Sponsors
lead

TYK Medicines, Inc

INDUSTRY